<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643148</url>
  </required_header>
  <id_info>
    <org_study_id>DCQ</org_study_id>
    <nct_id>NCT01643148</nct_id>
  </id_info>
  <brief_title>The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer</brief_title>
  <acronym>leptin</acronym>
  <official_title>Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materno-Perinatal Hospital of the State of Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Autonoma del Estado de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Materno-Perinatal Hospital of the State of Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen
      (CA) 15-3 together as reliable biomarkers for breast cancer.

      Patients:

      Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.

      Interventions:

      Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of
      cancer and patients with benign breast disease as well as biochemical tests of leptin,
      adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC),
      high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to
      analyze CA 15-3 levels with a electrochemiluminescence immunoassay.

      Hypothesis:

      Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect
      high risk women to develop breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical
      parameters were analyzed in 88 female patients attending mammography study. Predictive values
      of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">88</enrollment>
  <condition>Female Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>breast cancer patients (cases)</arm_group_label>
    <description>36 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>36 subjects</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cross-sectional prospective study conducted at the Maternal-Perinatal Hospital &quot;Mónica
        Pretelini&quot; (HMPMP), State of Mexico Health Institute (ISEM), Toluca, Mexico, from January
        to October 2011.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients attending mammography, average age of the fourth and fifth decades.

        Exclusion Criteria:

          -  Patients with hormonal therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonnathan Guadalupe Santillán Benítez, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Autonomus University Of the State Of México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leobardo Manuel Gómez Oliván, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Autonoma del Estado de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Mendieta Zeron, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Autonomous University of the State of Mexico</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Materno-Perinatal Hospital of the State of Mexico</investigator_affiliation>
    <investigator_full_name>Hugo Mendieta Zeron</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>BMI</keyword>
  <keyword>breast cancer</keyword>
  <keyword>CA-15-3</keyword>
  <keyword>leptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

